Galectin (GALT) Misses Q3 EPS by 2c; Updates on GR-MD-02 Phase 1 Cohort 1

November 12, 2013 8:34 AM

Galectin (NASDAQ: GALT) reported Q3 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20).

Galectin reported that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found